<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02821559</url>
  </required_header>
  <id_info>
    <org_study_id>EROS</org_study_id>
    <secondary_id>2011-005811-96</secondary_id>
    <nct_id>NCT02821559</nct_id>
  </id_info>
  <brief_title>Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer</brief_title>
  <acronym>EROS</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospira, now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <brief_summary>
    <textblock>
      Raltitrexed is a potent thymidylate synthase (TS) inhibitor. Conversely to 5-fluorouracil&#xD;
      (5FU), raltitrexed can be administered safely in patients with cardiovascular disease, as&#xD;
      well as in patients with dihydropyrimidine dehydrogenase deficit. Since raltitrexed is&#xD;
      administered in 15-minutes infusion, complications related to continuous infusion can be&#xD;
      avoided, and it becomes a potential good candidate for locoregional treatments as hepatic&#xD;
      intra-arterial or intra-peritoneal infusion. Despite these potential benefits over 5FU,&#xD;
      clinical trials failed in their temptation to replace the 5FU in colorectal cancer patients,&#xD;
      mainly due to raltitrexed toxicity at 3mg/m2 every 3 weeks. Oxaliplatin has demonstrated a&#xD;
      synergic effect when combined with TS inhibitors, and its association with raltitrexed was&#xD;
      evaluated at 130mg/m2 of oxaliplatin and 3mg/m2 of raltitrexed, every 3 weeks. Actually, one&#xD;
      of the first-line standard regimens in metastatic colorectal cancer patients is the biweekly&#xD;
      FOLFOX (85mg/m2 of oxaliplatin, and infusional 5FU) plus bevacizumab regimen, since a&#xD;
      significant progression-free survival (PFS) benefit was observed over FOLFOX plus placebo.&#xD;
      Biweekly administration of raltitrexed at 2mg/m2 demonstrated a favorable toxicity profile&#xD;
      even in patients aged &gt;65 years. Besides, the association of raltitrexed, oxaliplatin and&#xD;
      bevacizumab seems safe.&#xD;
&#xD;
      Then, the investigators decided to perform a randomized pharmacokinetic comparative study&#xD;
      between biweekly TOMOX (raltitrexed 2 mg/m2 and oxaliplatin 85mg/m2) and triweekly TOMOX&#xD;
      (raltitrexed 3 mg/m2 and oxaliplatin 130mg/m2) regimens in metastatic colorectal cancer&#xD;
      patients, in a &quot;ping-pong&quot; crossover strategy to reduce the intra-individual variability.&#xD;
      Bevacizumab was allowed at the dose of 5mg/kg or 7.5mg/kg, in biweekly and triweekly&#xD;
      schedules, respectively. The secondary end-points were, objective response rate evaluated by&#xD;
      RECIST 1.1 criteria, PFS, overall survival (OS), toxicity, and the comparison of toxicity&#xD;
      between two arms for the first 2 cycles.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of Raltitrexed plasma levels</measure>
    <time_frame>at 5 minutes, at 40 minutes, at 2 hours, at 7,5 hours, at 24 hours and at 14 days after each raltitrexed administration</time_frame>
    <description>pharmacokinetic study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>3 months</time_frame>
    <description>comparison of number of treatment-related adverse events between two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate evaluated by RECIST 1.1 criteria</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>from date to randomization to date of first progression of the disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>from date to randomization to date of death from any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>triweekly then biweekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The arm A consisted of 2 cycles of triweekly TOMOX (standard dose 3mg/m2 of Raltitrexed in 15-minutes infusion, and 130mg/m2 of oxaliplatin in 2h infusion, every 3 weeks), followed by 2 cycles of biweekly TOMOX (2mg/m2 of Raltitrexed in 15-minutes infusion, and 85mg/m2 of oxaliplatin in 2h infusion, every 2 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>biweekly then triweekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The arm B consisted of the reserve sequence starting with 2 cycles of biweekly TOMOX followed by 2 cycles of triweekly TOMOX regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TOMOX</intervention_name>
    <arm_group_label>biweekly then triweekly</arm_group_label>
    <arm_group_label>triweekly then biweekly</arm_group_label>
    <other_name>Tomudex-Oxaliplatin</other_name>
    <other_name>Raltitrexed-Oxaliplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab was allowed and used at 7,5 mg/kg or 5 mg/kg every 2 weeks.</description>
    <arm_group_label>biweekly then triweekly</arm_group_label>
    <arm_group_label>triweekly then biweekly</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  performance status (ECOG-PS) of 0 or 1&#xD;
&#xD;
          -  patient with histologically proven colorectal cancer with distant metastases&#xD;
&#xD;
          -  measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version&#xD;
             1.1&#xD;
&#xD;
          -  life expectancy &gt; 12 months&#xD;
&#xD;
          -  signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  prior chemotherapy at metastatic stage&#xD;
&#xD;
          -  presence of brain or meningeal metastases&#xD;
&#xD;
          -  other malignancies in the past 5 years with the exception of adequately treated&#xD;
             carcinoma in situ of the cervix and squamous or basal cell carcinoma of the skin&#xD;
&#xD;
          -  preexisting peripheral neuropathy&#xD;
&#xD;
          -  known hypersensitivity to any component of the study treatment&#xD;
&#xD;
          -  any psychiatric condition compromising the understanding of information or conduct of&#xD;
             the study&#xD;
&#xD;
          -  pregnancy, breast-feeding or absence of adequate contraception for fertile patients&#xD;
&#xD;
          -  patient under guardianship, curator or under the protection of justice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHRU de Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>March 29, 2016</study_first_submitted>
  <study_first_submitted_qc>June 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2016</study_first_posted>
  <last_update_submitted>June 29, 2016</last_update_submitted>
  <last_update_submitted_qc>June 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>raltitrexed</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>biweekly</keyword>
  <keyword>triweekly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Raltitrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

